1091 related articles for article (PubMed ID: 9300036)
21. tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.
Wu F; Garcia J; Sigman D; Gaynor R
Genes Dev; 1991 Nov; 5(11):2128-40. PubMed ID: 1936997
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors.
Ambrosino C; Ruocco MR; Chen X; Mallardo M; Baudi F; Trematerra S; Quinto I; Venuta S; Scala G
J Biol Chem; 1997 Jun; 272(23):14883-92. PubMed ID: 9169458
[TBL] [Abstract][Full Text] [Related]
23. Examination of TAR-independent Trans activation by human immunodeficiency virus type 1 Tat in human glial cells.
Kim YS; Panganiban AT
J Neurosci Res; 1996 Mar; 43(6):652-66. PubMed ID: 8984195
[TBL] [Abstract][Full Text] [Related]
24. Activation of HIV-1 transcription by Tat in cells derived from the CNS: evidence for the participation of NF-kappa B--a review.
Taylor JP; Khalili K
Adv Neuroimmunol; 1994; 4(3):291-303. PubMed ID: 7874398
[TBL] [Abstract][Full Text] [Related]
25. Synergism between Tat and VP16 in trans-activation of HIV-1 LTR.
Ghosh S; Selby MJ; Peterlin BM
J Mol Biol; 1993 Dec; 234(3):610-9. PubMed ID: 8254663
[TBL] [Abstract][Full Text] [Related]
26. The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription.
Rittner K; Churcher MJ; Gait MJ; Karn J
J Mol Biol; 1995 May; 248(3):562-80. PubMed ID: 7752225
[TBL] [Abstract][Full Text] [Related]
27. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages.
Murphy KM; Sweet MJ; Ross IL; Hume DA
J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418
[TBL] [Abstract][Full Text] [Related]
28. Lack of responsiveness of a nuclear factor-kappaB-regulated promoter to transactivation by human immunodeficiency virus 1 Tat in HeLa cells.
Kelly GD; Morris CB; Offermann MK
Virology; 1999 Oct; 263(1):128-38. PubMed ID: 10544088
[TBL] [Abstract][Full Text] [Related]
29. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
Chang LJ; Zhang C
Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
[TBL] [Abstract][Full Text] [Related]
30. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA.
Garber ME; Mayall TP; Suess EM; Meisenhelder J; Thompson NE; Jones KA
Mol Cell Biol; 2000 Sep; 20(18):6958-69. PubMed ID: 10958691
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides.
Arzumanov A; Walsh AP; Rajwanshi VK; Kumar R; Wengel J; Gait MJ
Biochemistry; 2001 Dec; 40(48):14645-54. PubMed ID: 11724578
[TBL] [Abstract][Full Text] [Related]
32. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter.
Brès V; Kiernan RE; Linares LK; Chable-Bessia C; Plechakova O; Tréand C; Emiliani S; Peloponese JM; Jeang KT; Coux O; Scheffner M; Benkirane M
Nat Cell Biol; 2003 Aug; 5(8):754-61. PubMed ID: 12883554
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR.
Jeyaseelan R; Kurabayashi M; Kedes L
AIDS Res Hum Retroviruses; 1996 May; 12(7):569-76. PubMed ID: 8743082
[TBL] [Abstract][Full Text] [Related]
34. Tackling Tat.
Karn J
J Mol Biol; 1999 Oct; 293(2):235-54. PubMed ID: 10550206
[TBL] [Abstract][Full Text] [Related]
35. Optimal Tat-mediated activation of the HIV-1 LTR promoter requires a full-length TAR RNA hairpin.
Verhoef K; Tijms M; Berkhout B
Nucleic Acids Res; 1997 Feb; 25(3):496-502. PubMed ID: 9016587
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.
Mhashilkar AM; Biswas DK; LaVecchio J; Pardee AB; Marasco WA
J Virol; 1997 Sep; 71(9):6486-94. PubMed ID: 9261367
[TBL] [Abstract][Full Text] [Related]
37. A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat.
Taylor JP; Pomerantz RJ; Oakes JW; Khalili K; Amini S
Oncogene; 1995 Jan; 10(2):395-400. PubMed ID: 7838536
[TBL] [Abstract][Full Text] [Related]
38. Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat.
Wu-Baer F; Sigman D; Gaynor RB
Proc Natl Acad Sci U S A; 1995 Aug; 92(16):7153-7. PubMed ID: 7638159
[TBL] [Abstract][Full Text] [Related]
39. Recruitment of the TATA-binding protein to the HIV-1 promoter is a limiting step for Tat transactivation.
Majello B; Napolitano G; Lania L
AIDS; 1998 Oct; 12(15):1957-64. PubMed ID: 9814863
[TBL] [Abstract][Full Text] [Related]
40. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.
Chen H; He J; Fong S; Wilcox G; Wood C
J Virol; 2000 Mar; 74(6):2703-13. PubMed ID: 10684286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
